Department of Chemistry and Biochemistry, University of Nevada, Las Vegas, United States
Kurt Reichermeier
Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, United States; Department of Discovery Proteomics, Genentech Inc, South San Francisco, United States; Department of Discovery Oncology, Genentech Inc, South San Francisco, United States
Daniel C Scott
Department of Structural Biology, St Jude Children's Research Hospital, Memphis, United States
Lorena Samentar
School of Life Sciences, University of Nevada, Las Vegas, United States; University of the Philippines, Iloilo, Philippines
Jasmin Coulombe-Huntington
Institute for Research in Immunology and Cancer, Department of Medicine, University of Montreal, Montreal, Canada
Luisa Izzi
Institute for Research in Immunology and Cancer, Department of Medicine, University of Montreal, Montreal, Canada
Xiaojing Tang
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada
Rebeca Ibarra
Department of Chemistry and Biochemistry, University of Nevada, Las Vegas, United States
Thierry Bertomeu
Institute for Research in Immunology and Cancer, Department of Medicine, University of Montreal, Montreal, Canada
Proteome Exploration Laboratory, Division of Biology and Biological Engineering, Beckman Institute, California Institute of Technology, Pasadena, United States
Proteome Exploration Laboratory, Division of Biology and Biological Engineering, Beckman Institute, California Institute of Technology, Pasadena, United States
Nora Caberoy
School of Life Sciences, University of Nevada, Las Vegas, United States
Brenda A Schulman
Max Planck Institute of Biochemistry, Molecular Machines and Signaling, Martinsried, Germany
Frank Sicheri
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada
Mike Tyers
Institute for Research in Immunology and Cancer, Department of Medicine, University of Montreal, Montreal, Canada
The cullin-RING ligases (CRLs) form the major family of E3 ubiquitin ligases. The prototypic CRLs in yeast, called SCF enzymes, employ a single E2 enzyme, Cdc34, to build poly-ubiquitin chains required for degradation. In contrast, six different human E2 and E3 enzyme activities, including Cdc34 orthologs UBE2R1 and UBE2R2, appear to mediate SCF-catalyzed substrate polyubiquitylation in vitro. The combinatorial interplay of these enzymes raises questions about genetic buffering of SCFs in human cells and challenges the dogma that E3s alone determine substrate specificity. To enable the quantitative comparisons of SCF-dependent ubiquitylation reactions with physiological enzyme concentrations, mass spectrometry was employed to estimate E2 and E3 levels in cells. In combination with UBE2R1/2, the E2 UBE2D3 and the E3 ARIH1 both promoted SCF-mediated polyubiquitylation in a substrate-specific fashion. Unexpectedly, UBE2R2 alone had negligible ubiquitylation activity at physiological concentrations and the ablation of UBE2R1/2 had no effect on the stability of SCF substrates in cells. A genome-wide CRISPR screen revealed that an additional E2 enzyme, UBE2G1, buffers against the loss of UBE2R1/2. UBE2G1 had robust in vitro chain extension activity with SCF, and UBE2G1 knockdown in cells lacking UBE2R1/2 resulted in stabilization of the SCF substrates p27 and CYCLIN E as well as the CUL2-RING ligase substrate HIF1α. The results demonstrate the human SCF enzyme system is diversified by association with multiple catalytic enzyme partners.